Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 5, 2007

BioVectra to Manufacture Helix’ Lung Cancer Candidate

  • Helix BioPharma signed an agreement with BioVectra to manufacture L-DOS47 bulk drug product for clinical testing in patients with adenocarcinoma of the lung. "BioVectra is a natural choice for our clinical manufacturing program requirements because in addition to their high calibre capabilities in the cGMP production of biopharmaceuticals, they are also one of the largest North American producers of the urease substance at the heart of our L-DOS47 drug product," notes John Docherty, Helix' vp of corporate development.

    During 2007, Helix intends to complete the remaining preclinical animal testing work with L-DOS47, in parallel with finalizing its clinical manufacturing activities.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »